Table 1. . Base case main model assumptions.

No.	Base case main model assumptions	Study, year	Ref.
1	The probability of hip/pelvic, vertebral, and wrist/arm fractures with RIS-GR and ALN were obtained from the cohort study by Thomasius et al.	Thomasius, 2022	[13]
2	Treatment persistence over 5 years was obtained from the observational study by Thomasius et al.	Thomasius, 2022	[13]
3	The effect of treatment was assumed to be maintained for two years (years 4 and 5) after its discontinuation.	Darbá, 2015	[21]
4	The mortality of the patient without fracture was obtained from the National Institute of Statistics.	INE, 2022	[22]
5	The mortality of the patient with fracture was obtained from a previously published Spanish study.	Darbá, 2015	[21]
6	The cost of fractures in Spain was calculated as the average of public prices in the regions that have specific prices for the three fractures considered or their DRGs. The average cost of the fractures was calculated according to the percentages observed in Thomasius et al.	Public prices Bartra, 2019; Thomasius, 2022	[13,19]
7	Pharmacological cost was obtained from retail prices (PVP) plus VAT, available in the BotPlus web database.	BotPlus, 2022	[20]
8	The utilities were obtained from the study by Hiligsmann et al. and Darbá et al.	Darbá, 2015; Hiligsmann, 2019	[14,21]

ALN: Weekly alendronate 70 mg tablets; PVP: Drug retail price; RIS-GR: Weekly gastro-resistant risedronate 35 mg gastro-resistant tablets; VAT: Value added tax.